[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100613936","phase-4-individualized-multiplex-pathophysiological-treatment-of-severe-acute-infections-n-acetylcysteine-100613936",false,"NCT07273071","Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine","A Randomized, Placebo-controlled, Blinded, Parallel-group Clinical Trial to Assess the Efficacy of N-acetylcysteine in Adults With Acute Infections or Sepsis and Evidence of Liver Dysfunction: the IMPACT-NAC Trial","IMPACT-NAC","Inclusion criteria\n\n1. Age ≥18 years\n2. Documented clinical suspicion of infection\n3. Model for end-stage liver disease (MELD) score ≥9\n\nExclusion criteria\n\n1. Admitted to hospital \\>24 hours before randomization\n2. Any previous severe anaphylaxis\n3. Other known allergy to N-acetylcysteine\n4. Ongoing treatment with N-acetylcysteine at randomization\n5. Documented clinical suspicion of bile duct obstruction\n6. Refractory circulatory shock\n7. Informed consent not obtainable\n8. Inability to read and understand Danish to a degree that allows valid informed consent and completion of trial assessments\n9. Involuntary admission under the psychiatric law\n10. Expected initiation of palliative care within 48 hours of randomization\n11. Ongoing treatment with nitroglycerin\n12. Any other condition deemed by the investigator to compromise patient safety or trial integrity (e.g., severe coagulopathy, uncontrolled bleeding, diabetic ketoacidosis)","ALL","18 Years",{"count":20,"type":21},360,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The primary objective of the IMPACT-NAC trial is to assess the effects of N-acetylcysteine on survival and hospital length of stay in adults admitted to the emergency department with acute infection or sepsis and evidence of liver dysfunction.\n\nThe main question it aims to answer is: does N-acetylcysteine increase the number of days alive and out of the hospital within the first 14 days after enrolment in the trial?\n\nTo answer this question, we will conduct a randomized, double-blinded controlled trial of 360 participants.\n\nParticipants will be randomized to either N-acetylcysteine or placebo (normal saline without active drugs). This will be administered as an infusion during four hours within the first day of hospital admission.",[27,28,29],"Sepsis","Acute Infection","Severe Infection",[27,28,29,31,32],"Acetylcysteine","Liver dysfunction","NOT_YET_RECRUITING","2026-03-23",{"date":36,"type":37},"2026-03-27","ACTUAL",{"date":39,"type":21},"2026-07",{"date":41,"type":21},"2028-05",{"name":43,"class":44},"Theis S. Itenov","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100497515","phase-2-senolytics-to-slow-progression-of-sepsis-stop-sepsis-trial-100497515","NCT05758246","Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial","Inclusion Criteria:\n\n* Age \\>=65 years\n* Primary diagnosis of acute infection (per investigator judgment)\n* SOFA \\>1\n* Admission order to the hospital\n* Expected length of stay \\>=48 hours (per investigator judgment)\n\nExclusion Criteria:\n\n* Admission to the ICU\n* Vasopressors, mechanical ventilation, or dialysis\n* Comfort care only\n* Total bilirubin \\>3X or AST\u002FALT \\>4x upper limit of normal\n* eGFR \\\u003C 25 ml\u002F min\u002F 1.73 m2\n* Hemoglobin \\\u003C7 g\u002FdL; white blood cell count ≤ 2,000\u002Fmm3; absolute neutrophil count ≤1 x 10\\^9\u002F;, or platelet count ≤ 40,000\u002FμL\n* Known HIV, Hepatitis B, or Hepatitis C\n* Invasive fungal infection (per investigator judgment)\n* Uncontrolled effusions or ascites (per investigator judgment)\n* New\u002Factive invasive cancer except non-melanoma skin cancers\n* Known hypersensitivity or allergy to Fisetin.\n* Active treatment with potential drug-drug interactions\n* Enrolled in another sepsis clinical trial","65 Years",{"count":54,"type":21},220,[56],"PHASE2","The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients. The central hypothesis is that a threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs, contributing to a disproportionate burden of sepsis in older patients. The study hypothesizes timely treatment with fisetin will interrupt this pathway.\n\nA multicenter, randomized, adaptive allocation clinical trial to identify the most efficacious dose of the senolytic fisetin to reduce the composite cardiovascular, respiratory, and renal sequential organ failure assessment score at 1 week, and predict the probability of success of a definitive phase III clinical trial.",[27,28,59],"Organ Failure","RECRUITING","2025-10-13",{"date":63,"type":37},"2025-10-15",{"date":65,"type":37},"2023-08-23",{"date":67,"type":21},"2026-08-23",{"name":69,"class":44},"University of Minnesota",10]